Open Access Open Badges Original investigation

Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study

Agnieszka Kaplon-Cieslicka1*, Marek Postula23, Marek Rosiak2, Michal Peller1, Agnieszka Kondracka4, Agnieszka Serafin1, Ewa Trzepla5, Grzegorz Opolski1 and Krzysztof J Filipiak1

Author Affiliations

1 1st Chair and Department of Cardiology, Medical University of Warsaw, Public Central Teaching Hospital in Warsaw, 1a Banacha St., Warsaw 02-097, Poland

2 Department of Noninvasive Cardiology and Hypertension, Central Clinical Hospital, the Ministry of the Interior, Warsaw, Poland

3 Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

4 Chair and Department of Internal Diseases and Endocrinology, Medical University of Warsaw, Warsaw, Poland

5 Medical Centre, Medical University of Warsaw, Warsaw, Poland

For all author emails, please log on.

Cardiovascular Diabetology 2014, 13:112  doi:10.1186/s12933-014-0112-0

Published: 15 August 2014



Evidence from the literature suggests diminished acetylsalicylic acid (ASA) treatment efficacy in type 2 diabetes (DM2). High on-aspirin platelet reactivity (HAPR) in DM2 has been linked to poor glycemic and lipid control. However, there are no consistent data on the association between HAPR and insulin resistance or adipose tissue metabolic activity. The aim of this study was to assess the relationship between laboratory response to ASA and metabolic control, insulin resistance and adipokines in DM2.


A total of 186 DM2 patients treated with oral antidiabetic drugs and receiving 75 mg ASA daily were included in the analysis. Response to ASA was assessed by measuring serum thromboxane B2 (TXB2) concentration and expressed as quartiles of TXB2 level. The achievement of treatment targets in terms of glycemic and lipid control, insulin resistance parameters (including Homeostatic Model Assessment-Insulin Resistance, HOMA-IR, index), and serum concentrations of high-molecular weight (HMW) adiponectin, leptin and resistin, were evaluated in all patients. Univariate and multivariate logistic regression analyses were performed to determine the predictive factors of serum TXB2 concentration above the upper quartile and above the median.


Significant trends in age, body mass index (BMI), HOMA-IR, HMW adiponectin concentration, C-reactive protein concentration and the frequency of achieving target triglyceride levels were observed across increasing quartiles of TXB2. In a multivariate analysis, only younger age and higher BMI were independent predictors of TXB2 concentration above the upper quartile, while younger age and lower HMW adiponectin concentration were predictors of TXB2 concentration above the median.


These results suggest that in DM2, the most important predictor of HAPR is younger age. Younger DM2 patients may therefore require total daily ASA doses higher than 75 mg, preferably as a twice-daily regimen, to achieve full therapeutic effect. Higher BMI and lower HMW adiponectin concentration were also associated with less potent ASA effect. This is the first study to demonstrate an association of lower adiponectin concentration with higher serum TXB2 level in patients treated with ASA.

Aspirin; Platelet aggregation; Diabetes mellitus; Insulin resistance; Adipokines